© 2004 European Society for Medical Oncology
Original Article |
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
1 Catholic University of Sacred Heart, Rome, Italy; 2 Szt Margarit Hospital, Budapest, Hungary; 3 III Med. Klinik, Munich, Germany; 4 All Union CRC, Moscow, Russia; 5 Estonian Oncology Center, Tallin, Estonia; 6 Hielkoskopie Centrum, Poznan, Poland; 7 Moscow Oncological Center, Moscow, Russia; 8 Aventis Pharma, Antony; 9 Institut Claudius Regaud, Toulouse, France
* Correspondence to: Dr C. Barone, Medical Oncology, Catholic University of the Sacred Heart, Largo Francesco Vito, 1.00168 Rome, Italy. Tel: +39-06-3015-4844; Fax: +39-06-3017-334; Email: carlobarone{at}rm.unicatt.it
Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial.
Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v.) and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks.
Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n=59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n=56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P < 0.0001), with median survival times of 10.7 and 6.9 months, respectively (P=0.0018). The major toxicity was grade 3/4 neutropenia, which was more pronounced with irinotecan/cisplatin than with irinotecan/5-FU/FA (65.7% versus 27%). Diarrhea was the main grade 3/4 non-hematological toxicity with both irinotecan/5-FU/FA (27.0%) and irinotecan/cisplatin (18.1%).
Conclusions: Both combinations were active, with acceptable safety profiles. Irinotecan/5-FU/FA was selected as the most effective combination for investigation in a phase III trial in advanced gastric cancer.
Key words: advanced gastric cancer, cisplatin, 5-FU/FA, irinotecan, phase II
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Moehler, S. Kanzler, M. Geissler, J. Raedle, M. P. Ebert, S. Daum, D. Flieger, T. Seufferlein, P. R. Galle, T. Hoehler, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction Ann. Onc., January 1, 2010; 21(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sahin, M. Koslowski, K. Dhaene, D. Usener, G. Brandenburg, G. Seitz, C. Huber, and O. Tureci Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development Clin. Cancer Res., December 1, 2008; 14(23): 7624 - 7634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dank, J. Zaluski, C. Barone, V. Valvere, S. Yalcin, C. Peschel, M. Wenczl, E. Goker, L. Cisar, K. Wang, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann. Onc., August 1, 2008; 19(8): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pozzo and C. Barone Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents? Oncologist, July 1, 2008; 13(7): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Park, E. Nam, J. Park, E. K. Cho, D. B. Shin, J. H. Lee, W. K. Lee, M. Chung, and S. I. Lee Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer Ann. Onc., April 1, 2008; 19(4): 729 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-G. Kim, S. Y. Oh, H.-C. Kwon, S. Lee, J. H. Kim, S.-H. Kim, and H.-J. Kim A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym103v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Lee, W. Kang, J. Kwon, S. Oh, H. Lee, H. Kim, B. Park, H. Lim, M. Han, J. Park, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Ann. Onc., January 1, 2007; 18(1): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Shah, R. K. Ramanathan, D. H. Ilson, A. Levnor, D. D'Adamo, E. O'Reilly, A. Tse, R. Trocola, L. Schwartz, M. Capanu, et al. Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma J. Clin. Oncol., November 20, 2006; 24(33): 5201 - 5206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Ichikawa and Y Sasaki Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann. Onc., November 1, 2006; 17(11): 1665 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data J. Clin. Oncol., June 20, 2006; 24(18): 2903 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ohtsu, S. Yoshida, and N. Saijo Disparities in Gastric Cancer Chemotherapy Between the East and West J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero, T. Macarulla, F. J. Ramos, and J. Baselga Novel targeted therapies in the treatment of gastric and esophageal cancer Ann. Onc., November 1, 2005; 16(11): 1740 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani Evolving Chemotherapy for Advanced Gastric Cancer Oncologist, October 1, 2005; 10(suppl_3): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takiuchi, H. Narahara, T. Tsujinaka, M. Gotoh, S.-i. Kawabe, K.-i. Katsu, H. Iishi, M. Tatsuta, K. Fujitani, H. Furukawa, et al. Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002) Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bouche, M. Ychou, P. Burtin, L. Bedenne, M. Ducreux, G. Lebreton, J. Baulieux, B. Nordlinger, C. Martin, J. F. Seitz, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann. Onc., September 1, 2005; 16(9): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Shah, D. Ilson, and D. P. Kelsen Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy J. Clin. Oncol., April 10, 2005; 23(11): 2574 - 2576. [Full Text] [PDF]
|
|